21 results
424B3
QTTB
Q32 Bio Inc.
29 Apr 24
Prospectus supplement
5:10pm
.
Our Strategy
Our mission is to develop therapeutics that restore healthy immune regulation for patients with severe autoimmune and inflammatory
8-K
EX-99.3
QTTB
Q32 Bio Inc.
26 Mar 24
Q32 Bio Announces Closing of Merger with Homology Medicines and Concurrent Private Placement of $42 Million
9:57pm
Innovation Fund and Sanofi Ventures.
Our Strategy
Our mission is to develop therapeutics that restore healthy immune regulation for patients with severe
8-K
EX-99.1
QTTB
Q32 Bio Inc.
26 Jan 24
Regulation FD Disclosure
4:13pm
capital structure. 4
Q32 Mission: Building The Future of Immune Therapeutics Bempikibart (ADX-914): Dual inhibitor of IL-7 and TSLP signaling, designed … basket Anticipated Milestones 1. Assuming closing mid-1Q 2024. * Based on current management estimates 34
Q32 Mission: Building The Future of Immune
425
QTTB
Q32 Bio Inc.
26 Jan 24
Business combination disclosure
12:00am
in which we will operate, developments in our business and operations and changes in our capital structure. 4
Q32 Mission: Building The Future … . * Based on current management estimates 34
Q32 Mission: Building The Future of Immune Therapeutics Bempikibart (ADX-914): Dual inhibitor of IL-7
425
kitwnjakjs0fz6o1o lt
16 Nov 23
Business combination disclosure
4:19pm
425
ws4 h5qg4i
16 Nov 23
Business combination disclosure
7:17am
8-K
EX-99.2
oiiaiqrtu 4qxisis
16 Nov 23
Q32 Bio and Homology Medicines Announce Merger Agreement
7:16am
8-K
EX-99.1
vi2mdn3 93
8 Feb 21
Other Events
4:07pm
8-K
EX-99.1
7tvpvo hqfp4c8zivi3f
6 Jan 21
Regulation FD Disclosure
8:01am